Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Loda

Showing results (161-170 of 409) with videos related to

Pageof 41
Sort By:
JAMA Internal Medicine|June 3, 2014
5α-Reductase inhibitors and risk of high-grade or lethal prostate cancerMark A Preston, Kathryn M Wilson, Sarah C Markt, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2005
p63 regulates commitment to the prostate cell lineageSabina Signoretti, Maira M Pires, Meghan Lindauer, et al.
Cancer & Metabolism|August 7, 2024
The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cellsGuilherme Henrique Tamarindo, Caroline Fidalgo Ribeiro, Alana Della Torre Silva, et al.
BJU International|November 8, 2008
P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cellsJessica A Mandeville, Brasil Silva Neto, Alex J Vanni, et al.
BJU International|January 26, 2016
Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrenceSarah M Rudman, Kathryn P Gray, Julie L Batista, et al.
Cancer Research|September 24, 2009
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagyBala S Balakumaran, Alessandro Porrello, David S Hsu, et al.
Molecular Cancer Research : MCR|January 7, 2017
Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor MicroenvironmentLisa Staunton, Claire Tonry, Rosina Lis, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 31, 2025
Antibody-Based Multiplex Image Analysis: Standard Analytical Workflows and Artificial Intelligence Tools for PathologistsMohamed Omar, Giuseppe Nicolo' Fanelli, Fabio Socciarelli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2023
Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association StudyChaoran Ma, Xiaoyu Wang, James Y Dai, et al.
The Journal of Biological Chemistry|April 2, 2005
Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp miceTerence M Williams, Ghada S Hassan, Jiangwei Li, et al.
Pageof 41

Showing results (161-170 of 409) with videos related to

Sort By:
Pageof 41
JAMA Internal Medicine|June 3, 2014
5α-Reductase inhibitors and risk of high-grade or lethal prostate cancerMark A Preston, Kathryn M Wilson, Sarah C Markt, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2005
p63 regulates commitment to the prostate cell lineageSabina Signoretti, Maira M Pires, Meghan Lindauer, et al.
Cancer & Metabolism|August 7, 2024
The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cellsGuilherme Henrique Tamarindo, Caroline Fidalgo Ribeiro, Alana Della Torre Silva, et al.
BJU International|November 8, 2008
P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cellsJessica A Mandeville, Brasil Silva Neto, Alex J Vanni, et al.
BJU International|January 26, 2016
Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrenceSarah M Rudman, Kathryn P Gray, Julie L Batista, et al.
Cancer Research|September 24, 2009
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagyBala S Balakumaran, Alessandro Porrello, David S Hsu, et al.
Molecular Cancer Research : MCR|January 7, 2017
Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor MicroenvironmentLisa Staunton, Claire Tonry, Rosina Lis, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 31, 2025
Antibody-Based Multiplex Image Analysis: Standard Analytical Workflows and Artificial Intelligence Tools for PathologistsMohamed Omar, Giuseppe Nicolo' Fanelli, Fabio Socciarelli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2023
Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association StudyChaoran Ma, Xiaoyu Wang, James Y Dai, et al.
The Journal of Biological Chemistry|April 2, 2005
Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp miceTerence M Williams, Ghada S Hassan, Jiangwei Li, et al.
Pageof 41